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26 Abstract 
 
27 
 
28 Context:         Population studies frequently measure cortisol as a marker of stress and excess 
 
29 cortisol is associated with increased mortality. Cortisol has a circadian rhythm and frequent 
 
30 blood sampling is impractical to assess exposure. We investigated measuring salivary cortisone 
 
31 and examined sampling frequency required to determine cortisol exposure. 
 
32 
 
33 Methods:  Serum  and  saliva  with  cortisol  and  cortisone  measured   by  LC-MS/MS      in 
 
34 independent  cohorts.  The  relationship  between  serum  cortisol  and  salivary cortisone was 
 
35 analysed in cohort 1 using a linear mixed effects model and resulting fixed effects component 
 
36 was applied to cohort 2. Saliva cannot easily be collected when sleeping so we determined 
 
37 minimum sampling required to estimate cortisol exposure (eAUC) using 24-hour cortisol 
 
38 profiles (AUC24) and calculated the relative error (RE - a measure similar to the coefficient of 
 
39 variation) for the eAUC. 
 
40 
 
41 Results: >90% of variability in salivary cortisone could be accounted for by change in serum 
 
42 cortisol. A single serum cortisol measurement was a poor estimate of AUC24  especially in the 
 
43 morning or last thing at night (RE > 68%), however 3 equally spaced samples gave a  median 
 
44 RE of 0% (Interquartile range (IQR) between -15.6% and 15.1%). In patients with adrenal 
 
45 incidentalomas the eAUC based on 3 serum cortisol samples showed a difference between 
 
46 those with autonomous cortisol secretion and those without (p=0.03). 
 
47 
 
48 Interpretation: Accepting that most people sleep 7-8 hours, using approximately 8-hourly 
 
49 salivary  cortisone  measurements  provides  a  non-invasive  method  of  estimating   24-hour 
 
50 cortisol exposure for population studies. 
 
51 
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52 Introduction 
 
53 
 
54 Measuring cortisol exposure is important in defining health. Even a subtle increase in cortisol 
 
55 exposure may affect health outcomes and increased cardiovascular risk and mortality are 
 
56 reported  in  shift  workers  and  in  patients  with  sleep  apnoea  and  functioning       adrenal 
 
57 incidentalomas (1-5). Cortisol deficiency, irrespective of treatment with glucocorticoids, is also 
 
58 associated with elevated mortality rates and a poor quality of life (6,7). In health, serum cortisol 
 
59 demonstrates a distinct circadian rhythm rising from between 0200-0400h to peak shortly after 
 
60 waking and declining over the day to low levels in the evening with a nadir around 2400h (8). 
 
61 Results from a large number of studies from the 1960s to today and using different assays are 
 
62 very consistent regarding this 24-hour rhythm (9). The circadian rhythm of cortisol is  altered 
 
63 in shift workers in relation to changes in the sleep-wake cycle and this results in increased 
 
64 cortisol exposure as judged by the 24-hour area under the curve (AUC) of cortisol (10). The 
 
65 same is true for patients with functioning adrenal incidentalomas who have high nocturnal 
 
66 cortisol exposure (11). 
 
67 
 
68 The cortisol circadian rhythm has a period of ~24 hours and can be described mathematically 
 
69 by a Fourier Series (cosinor model) (12). Mathematical principles teach us that, in the absence 
 
70 of measurement inaccuracies and other disturbances, the mesor (mean) can be estimated, 
 
71 precisely,  by taking the  mean  of  any number  of  equi-spaced  samples  exceeding the  total 
 
72 number of harmonically related sinusoidal  components (harmonics).   Because the mesor    is 
 
73 proportional to the AUC of a periodic function (AUC = mesor x period) this provides a means 
 
74 of estimating AUC. However, the cortisol circadian rhythm within individuals has  biological 
 
75 variability and absolute  cortisol  levels  may be  determined by other factors such as   genetic 
 
76 sensitivity to glucocorticoids, cortisol production rates and variations in clearance (13-15), but 
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77 overall the circadian rhythm of cortisol is similar between populations in different studies (9). 
 
78 Our earlier work suggests that the cortisol rhythm is well modelled by a two-harmonic  series 
 
79 (the mesor plus two harmonically-related sinusoidal components) suggesting, therefore,   that 
 
80 any three, or more, equi-spaced samples would lead to a reliable estimate of the mesor, hence 
 
81 AUC (16). Given the likely presence of random variation, taking a much larger number of equi- 
 
82 spaced samples would be expected to lead to improved estimates by reducing statistical 
 
83 variability, however, the need to minimise the number of samples in clinical trials militates 
 
84 against this. 
 
85 
 
86 Cortisol exposure can be estimated by measuring serum, salivary, interstitial and urine cortisol 
 
87 and each method has its advantages and disadvantages. The measurement of serum cortisol 
 
88 requires venepuncture and the stress of venepuncture may itself raise cortisol levels. Urine 
 
89 requires 24 hour collection, which is often incomplete and in all studies shows reduced 
 
90 sensitivity and specificity for diagnosing cortisol excess compared to measurement of   serum 
 
91 samples (17). Interstitial measurements require a complex custom sampling apparatus that   is 
 
92 not suitable to study large numbers of subjects. Salivary measurement has the advantage of 
 
93 being non-invasive, can be collected with little stress at home or work and samples are very 
 
94 stable, however sampling cannot be easily done during sleep. Salivary cortisone is   emerging 
 
95 as an improved measure of serum cortisol than salivary cortisol, because it is derived from 
 
96 serum free cortisol which is rapidly converted to cortisone in the salivary gland. Salivary 
 
97 cortisone is measurable at low levels of serum cortisol and is not affected by administration of 
 
98 oral hydrocortisone (16,18,19). 
 
99 
 
100 Many studies have used single measurements of serum or salivary cortisol to make conclusions 
 
101 about cortisol exposure especially in the field of psychology (20,21), however, in view of  the 
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102 circadian rhythm of cortisol, these studies are likely to be inaccurate and there is a need for  a 
 
103 more accurate estimate of cortisol exposure. We have previously shown that 94% of the 
 
104 variation in salivary cortisone is predicted by changes in serum cortisol (16). We have now 
 
105 tested this relationship between salivary cortisone and serum cortisol in another population of 
 
106 healthy individuals and in a patient population with adrenal incidentalomas some of whom had 
 
107 autonomous cortisol secretion. We have then looked at the frequency of sampling required  to 
 
108 estimate the AUC of cortisol over 24 hours using serum cortisol and salivary cortisone. 
 
109 
 
110 
 
111 Methods 
 
112 
 
113 Healthy  Volunteer and  Patient Cohorts: Cortisol  data from  three previously    published 
 
114 cohorts of healthy subjects and patients was used for analysis. Cohorts 1 & 2 had measurements 
 
115 of  both  serum  cortisol  and  salivary cortisone  and  were used  to  examine  the relationship 
 
116 between serum cortisol and salivary cortisone and all 3 cohorts had hourly measurement of 
 
117 serum cortisol and were used for analysis of sampling frequency. Meals were not standardised 
 
118 across studies and none of the women were on oestrogen containing therapy: 
 
119 x Cohort 1: Fourteen healthy male volunteers with a median (interquartile range  (IQR)) 
120 age of 28 (25 ± 36) years, weight 83 (75 ± 90) kg and BMI 25.3 (23.1 ± 26.3) kg/m2 
 
121 who had 24-hour, hourly sampling for serum cortisol and salivary cortisone from 0700- 
 
122 2200h measured by LC-MS/MS (16). 
 
123 x Cohort 2: Eight patients with adrenal incidentalomas and autonomous cortisol secretion 
 
124 (overnight dexamethasone suppression test serum cortisol >80nmol/L, or 60-80nmol/L 
 
125 with an ACTH <2.2pmol/L (10pg/mL), and no IHDWXUHVRIFOLQLFDO&XVKLQJ¶VDQG two 
 
126 matched groups (age-, sex- and BMI-matched): 6 patients with adrenal incidentalomas 
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127 and no excess cortisol secretion and 6 healthy volunteers. Median (IQR) age of 63 (61 
 
128 ± 67) years, weight 73 (63 ± 97) kg and BMI 28 (24 ± 33) kg/m2  who had 24-hour, 
 
129 hourly sampling of serum cortisol and hourly salivary cortisol/cortisone 0600h to 2300h 
 
130 measured by LC-MS/MS (11). 
 
131 x Cohort 3: 28 healthy (9 female) volunteers mean (range) age 28 (18±56) years who had 
 
132 undergone 24-hour, hourly serum cortisol profiling measured by LC-MS/MS (22). 
 
133 
 
134 Assays: LC-MS/MS analysis for serum and salivary cortisone was performed using a Waters 
 
135 Xevo TQ-MSTM mass spectrometer and a Waters AcquityTM   LC system with an electrospray 
 
136 source operated in positive ionisation mode (23). The lower limit of quantitation (LLOQ) for 
 
137 serum cortisol was 12.5nmol/L. The inter-assay imprecision was 8, 7 and 6% at 
 
138 concentrations of 80, 480 and 842nmol/L respectively.  Salivary cortisone was measured with 
 
139 a modified LC-MS/MS assay with lower limits of detection 0.50 nmol/L, intrassay CVs 
 
140 <7.9%; and interassay  <10.3% at 3.6±96 nmol/L of salivary cortisone (24). 
 
141 Statistical Analysis: All statistical analyses were performed using MatlabTM and Microsoft 
 
142 Excel 2010. In cohort 1, linear mixed effects models were used for both cosinor and 
 
143 regression analysis to account for intra- and inter-subject variability. Model selection was by 
 
144 likelihood-ratio test between models and statistically significant but more complex models 
 
145 with only marginal improvement in either the Akaike or Bayesian Information Criteria were 
 
146 rejected in favour of simplicity. The selected mixed effects model was found to be superior to 
 
147 its fixed effects equivalent (P<=0.001). For use in cohort 2, the random effects component of 
 
148 the mixed effects model was no longer applicable and so only the fixed effects element was 
 
149 retained. 
 
150 AUC estimation was conducted as follows. AUC24  was computed by the trapezium rule. One 
 
151 sample estimated AUC (eAUC): was computed as 24 times the sampled value. Two sample 
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152 eAUC: the earliest start-time was selected and the mean of the corresponding sample and the 
 
153 sample 12 hours later was computed and multiplied by 24. The start point was advanced by 
 
154 one hour and repeated until the sample was exhausted. Three sample eAUC: As above with 
 
155 samples at baseline, 8 & 16 hours and likewise for four samples. 
 
156 To account for inter-subject variability we derived the relative error (RE), a measure similar 
 
157 to the coefficient of variation. For each subject we computed the difference between the 
 
158 actual AUC (AUC24) and the under-sampled estimates, (eAUC) and divided by the AUC24, 
 
159 thus removing the inter-subject effect. 
 
160 The sensitivity analysis explored the loss of accuracy (deviation from eAUC) that occurs 
 
161 when samples are not taken at their prescribed times. This was done by taking all possible 
 
162 patterns of sampling one hour too early or too late and computing the relative deviation from 
 
163 WKH³RQ-WLPH´ estimate. 
 
164 A two-sample t-test with unequal variances was used to examine differences between patients 
 
165 with adrenal incidentalomas with and without subclinical hypercortisolism. 
 
166 Ethics: All subjects and patients gave full informed consent: cohort 1, the study received 
 
167 approval from the South East Wales Research Ethics Committee; cohort 2, the study received 
 
168 approval from East Leeds National Research Ethics Service Committee, cohort 3, the study 
 
169 was approved by the South Manchester Local Research Ethics Committee. 
 
170 
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171 
 
172 Results 
 
173 
 
174 Relationship between salivary cortisone and serum cortisol (figure 1): Application of the 
 
175 fixed effects model: log10 serum F = 1.24+0.89 log10  salE describing the relationship between 
 
176 serum cortisol and salivary cortisone in cohort 1 was applied to cohort 2 which included 
 
177 patients with adrenal incidentalomas with autonomous cortisol secretion  as well as matched 
 
178 controls. The fixed effects model from cohort 1 gave similar results in cohort 2: model 
 
179 predictions of serum cortisol from salivary cortisone gave correlation coefficients of r=0.93 
 
180 and 0.91 p<0.001, for cohorts 1 & 2 respectively. 
 
181 
 
182 Frequency of serum cortisol sampling and comparison of eAUC vs AUC24 (figure 2 & 
 
183 table 1): A single sample used to calculate the eAUC was a very poor predictor of the 
 
184 AUC24, especially in the morning and last thing at night. The median RE were greatest 
 
185 between 0700-0900h and 2300-0100h, being 104% to -68%, and the smallest values were 
 
186 between 0400-0500h and 1400-1600h, being -42% to 30%. The RE falls as 2, 3 and 4 equi- 
 
187 spaced samples are used to calculate the eAUC with the IQR for the RE with 3 equi-spaced 
 
188 samples being -15.6% to 15.1%,  and for 4 equi-spaced samples -14.3% to 11.4%. The same 
 
189 pattern was seen when the individual cohorts were analysed (Table1). 
 
190 
 
191 Sensitivity analysis on timing of samples: The 8-hourly sampling scheme is relatively 
 
192 insensitive to mistiming of the samples by up to one hour either way for any or all samples. 
 
193 Looking at the variation of the mistimed (± one hour) 3-sample eAUCs against the eAUC on- 
 
194 time across all three cohorts gives a median RE of 0% with IQR between -7.3% and 7.6%. 
 
195 
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196 Comparison of eAUC vs AUC24 in patients with adrenal incidentalomas with and 
 
197 without autonomous cortisol secretion (Figure 3): To test whether the eAUC could be used 
 
198 to distinguish different patient populations we examined the AUC24 and eAUC between 
 
199 healthy controls and patients with adrenal incidentaloma and autonomous cortisol secretion 
 
200 and those without autonomous cortisol secretion. There was a difference between AUC24 for 
 
201 patients with adrenal incidentalomas and autonomous cortisol secretion and those without 
 
202 (p<0.02) and the same pattern was seen for eAUC based on 3 serum cortisol samples 
 
203 S DQGDOWKRXJKWKHH$8&EDVHGRQVDOLYDU\FRUWLVRQHVDPSOHVGLGQ¶W reach 
 
204 significance (p=0.06) the pattern was the same. The 3 samples used for serum cortisol were 
 
205 0700, 1500, & 2300h but as there was no salivary sample at 0700h the 3 samples used for 
 
206 salivary cortisone were 0800, 1500 & 2300h. The 2300h salivary cortisone in patients with 
 
207 and without hypercortisolaemia showed that the 2300h salivary cortisone was higher in the 
 
208 patients with subclinical hypercortisolaemia: median (25-75 percentiles) controls 4.5, 4.0-7.9; 
 
209 SCH 9.9, 7.5-16.7  AI 4.4, 3.0-7.4 ANOVA p=0.03 with SCH different from AI and controls 
 
210 p<0.05. For the healthy men in cohort 1 the eAUC for salivary cortisone median (25-75 
 
211 percentiles) was 406 (387-470) nmol hours/L similar to that of the patients with adrenal 
 
212 incidentalomas and no autonomous cortisol secretion. 
 
213 
 
214 
 
215 
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216 Discussion 
 
217 
 
218 We have confirmed that salivary cortisone is a good estimate of serum cortisol in populations 
 
219 of both healthy subjects and patients. Examining the frequency of serum cortisol sampling, 
 
220 we demonstrate that a single cortisol sample is a poor measure of cortisol AUC, especially 
 
221 when taken around the time of waking and going to sleep.  However, three equi-spaced 8 
 
222 hourly serum cortisol samples give an eAUC with an inter-quartile range between -15.6% and 
 
223 15.1%. of the AUC24  and this was relatively insensitive to mistiming by one hour. Taken 
 
224 together these results suggest that three approximately 8 hourly spaced salivary cortisone 
 
225 measurements can give a good estimate of serum cortisol exposure in healthy and patient 
 
226 populations and provides an algorithm for measuring 24 hour cortisol exposure without 
 
227 interrupting sleep and that is independent of the time of starting sampling. 
 
228 
 
229 It is evident from our data that the single measurement of cortisol when taken in the morning 
 
230 or last thing at night has a poor correlation with overall 24-hour cortisol AUC. This is in 
 
231 accordance with the problem of AUC estimation from a small number of samples in data that 
 
232 has a periodic component. Estimates can only be unbiased if the number of samples exceeds 
 
233 the number of significant harmonic components needed to represent the curve, two in the 
 
234 case of cortisol. A single sample will always be biased unless its timing matches the point at 
 
235 which the curve crosses the mesor. From our data, the best times for a single measurement in 
 
236 relation to overall cortisol exposure is when the RE is lowest between either 1400±1600h in 
 
237 the afternoon or 0400±0500h in the morning corresponding to when the cortisol rhythm 
 
238 crosses the mesor as predicted by theory. Timing of a single sample is tricky in shift workers 
 
239 whereas taking 3 approximately 8 hourly samples allows sampling to start at any time. The 
 
240 cortisol circadian rhythm is described mathematically by a sinusoid with two harmonics and 
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241 as such 3 or more equally spaced samples taken over 24 hours should correlate well with the 
 
242 AUC24. This is what we observed. Increasing the number of samples will reduce variability in 
 
243 the estimates, however, 6 hourly or more frequent sampling is impractical because it would 
 
244 require sampling during sleep. We found that there was little difference in the accuracy of 
 
245 predicting the AUC24  between 8 hourly vs 6 hourly sampling, and even when samples were 
 
246 not taken exactly 8 hourly we found there was still a good correlation between the eAUC and 
 
247 AUC24. 
 
248 
 
249 We are not proposing the salivary cortisone eAUC as a diagnostic test for &XVKLQJ¶V 
 
250 syndrome and adrenal insufficiency, where we already have specific and sensitive tests and 
 
251 cortisol levels at specific times of the day are more relevant than the 24 hour cortisol 
 
252 exposure. The single measurement of either serum or salivary cortisol as a diagnostic test has 
 
253 EHHQXVHGLQPDQ\VWXGLHVWRLQYHVWLJDWH&XVKLQJ¶VV\QGURPHDQGGLVHDVH-27). A 
 
254 single late night cortisol measurement is a sensitive method for diagnosing &XVKLQJ¶V 
 
255 syndrome and has been shown to be elevated in some populations such as those with type 2 
 
256 diabetes (27), and in our study the single measurement of salivary cortisone at 2300h did 
 
257 differentiate function from non-functioning adrenal incidentalomas. However, cortisol 
 
258 H[SRVXUHKFRUWLVRO$8&YDULHVLQERWKSDWLHQWVZLWK&XVKLQJ¶VV\QGURPH adrenal 
 
259 insufficiency and there is overlap between patient populations and healthy individuals. A 
 
260 UHFHQWVWXG\LQSDWLHQWVZLWK&XVKLQJ¶VGLVHDVHVKRZHGJUHDWYDULDEility in late-night salivary 
 
261 cortisol within patients over time (28) and late night salivary cortisol is a poor marker 
 
262 differentiate functioning from non-functioning adrenal incidentalomas (29). We propose that 
 
263 the salivary cortisone eAUC provides an easy to administer more accurate method for 
 
264 comparing cortisol exposure in populations of patients or healthy subjects than single samples 
 
265 or 24 hour serum profiles. 
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266 
 
267 In our small cohort of patients with functioning adrenal incidentalomas, if samples were 
 
268 taken in the morning the excess cortisol secretion would be missed whereas, as shown by our 
 
269 data, a sample taken last thing at night or 3 samples taken approximately 8 hourly 
 
270 demonstrated that adrenal incidentalomas with excess cortisol secretion, as judged by a 
 
271 dexamethasone suppression test, had overall increased cortisol secretion compared to non- 
 
272 functioning adrenal incidentalomas. It is likely that adrenal tumours have more stable cortisol 
 
273 excreWLRQZKHUHDVLQ&XVKLQJ¶VGLVHDVHWKHUHPD\EHYDULDELOLW\RYHUWLPHKRZHYHU 3 
 
274 samples rather than 1 is likely to better define the variability related to disease. The salivary 
 
275 cortisone eAUC in the healthy men in cohort 1 was similar to that of patients with non- 
 
276 functioning adrenal incidentalomas, however this is not a normal range as a much bigger 
 
277 sample of the population would be required. We know in any population of healthy 
 
278 individuals and patients there is variation in 24-hour cortisol exposure and overlap between 
 
279 patients with excess and deficient cortisol secretion. Therefore, We know that meal times, 
 
280 shift work and stress can influence cortisol exposure so in studies comparing populations it is 
 
281 important to control for these factors. 
 
282 
 
283 Salivary cortisol has been used as a measurement of free cortisol since the 1960s (30) and 
 
284 now LC-MS/MS provides a highly specific and sensitive method whereby we can measure 
 
285 cortisol and cortisone simultaneously (31). Free serum cortisol is rapidly converted to 
 
286 cortisone in the salivary gland and salivary cortisone generally shows a better correlation 
 
287 with serum cortisol than salivary cortisol especially at low levels of serum cortisol where 
 
288 salivary cortisol is undetectable (19). We have previously shown that salivary cortisone 
 
289 reflects serum cortisol using a mixed effects model and we have now shown that its fixed 
 
290 effects component demonstrates an almost identical relationship in another healthy volunteer 
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291 population as well as in patients being investigated for adrenal incidentalomas, half of whom 
 
292 had functioning adrenal adenomas secreting cortisol. The results confirm that salivary 
 
293 cortisone is a good method for estimating serum cortisol levels and further studies are 
 
294 required to establish its use. Saliva has the advantage of being non-invasive, can be collected 
 
295 in a non-clinical setting and, because steroids are very stable, samples can be posted to the 
 
296 laboratory without any special conditions. 
 
297 
 
298 Limitations of our data are the retrospective analysis and that the patient population is 
 
299 relatively small. This is reflected in the fact that the difference in eAUC for salivary cortisone 
 
300 between patients with adrenal incidentalomas with or without excess cortisol secretion GLGQ¶W 
 
301 reach significance. However, the studies analysed provide comprehensive data of hourly 
 
302 sampling over 24 hours in 3 different subject cohorts and the results are consistent over the 
 
303 different cohorts. Although this analysis is retrospective all the studies were done under 
 
304 carefully monitored controlled conditions. It should be recognised that two AUCs can be the 
 
305 same but the rhythm may be different but it is difficult to define the rhythm from limited 
 
306 sampling and this will generally require more frequent sampling. 
 
307 
 
308 This study provides a strong basis for using three approximately 8 hourly spaced salivary 
 
309 cortisone samples when estimating cortisol exposure in healthy and patient populations. This 
 
310 methodology will allow further investigation of the impact of cortisol secretion on health. 
 
311 
 
312 
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313 Legends 
 
314 
 
315 Table 1: Relative Error (RE) for individual cohorts. 
 
316 
 
317 Figure 1: Shows the relationship between serum cortisol and salivary cortisone. Cohort 1 was 
 
318 analysed using a linear mixed effects model and the resulting fixed effects component was applied 
 
319 predictively to Cohort 2. The relationship is the same in both cohorts. 
 
320 
 
321 Figure 2: Box-plots of Relative Error with IQR and range across all cohorts using 1 to 4 equi-spaced 
 
322 sampling points in estimating AUC. The size of the Relative Error and variation over time decreases 
 
323 with the increasing number of samples measured. 
 
324 
 
325 Figure 3. AUC24 (a), eAUC for serum cortisol (b) and eAUC salivary cortisone (c) based on 3 
 
326 approximately equi-spaced samples in patients with Subclinical HyperCortisolism (SCH) and without 
 
327 autonomous cortisol section (AI) and adrenal incidentalomas. Boxes show IQR and dotted lines 
 
328 minimum and max range. 
 
329 
 
330 
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Table 1: Relative Error (RE) for individual cohorts. 
3-equi-spaced samples RE (%) 
 
 
 
 
 
4-equi-spaced samples RE (%) 
 
 median 25%ile 75%ile IQR 
Cohort 1 2.3 -6.61 6.77 13.4 
Cohort 2 -1.53 -7.23 3.37 10.6 
Cohort 3 -0.445 -12.1 5.05 17.2 
All -1.11 -14.3 11.4 25.7 
 median 25%ile 75%ile IQR 
Cohort 1 2.4 -16.5 20.7 37.1 
Cohort 2 -1.69 -2.37 1.55 3.92 
Cohort 3 -5.78 -11.7 9.39 21.1 
All -0.03 -15.6 15.1 30.6 
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